1) A woman who is in lactation period or who may be pregnant, or those who do not agree to prevent pregnancy by medically appropriate means for up to 7 days after study drug administration.Medically appropriate contraception means that using a combination of two or more of the following: not having sexual intercourse, taking surgical sterilization such as vasectomy or intrauterine device, taking oral contraceptive, using condom.2) A person who has severe liver damage (AST or ALT at the time of qualification test is more than 3 times the upper limit of institutional standard and total bilirubin is more than twice the upper limit of institutional standard value), renal disorder (eGFR of eligibility test value 30 mL/min/1.73m2 or less).3) A person with hypersensitivity to ivermectin.4) A person with a history of severe drug allergies such as Stevens-Johnson syndrome, toxic epidermal necrolysis.5) A person who has received the prohibited medication within the past month (within the past 6 months for biologics), or those who need to use the prohibited medication during the clinical trial period.6) Those who are scheduled to receive SARS-CoV-2 vaccination from the date of consent to the end of the follow-up period.7) A person who are currently participating in other clinical trials or who have participated in other clinical trials within 30 days before obtaining consent.8) In addition, a person who is determined to be unsuitable as a subject of this clinical trial by the principal investigator.

1) A woman who is in lactation period or who may be pregnant, or those who do not agree to prevent pregnancy by medically appropriate means for up to 7 days after study drug administration.Medically appropriate contraception means that using a combination of two or more of the following: not having sexual intercourse, taking surgical sterilization such as vasectomy or intrauterine device, taking oral contraceptive, using condom.2) A person who has severe liver damage (AST or ALT at the time of qualification test is more than 3 times the upper limit of institutional standard and total bilirubin is more than twice the upper limit of institutional standard value), renal disorder (eGFR of eligibility test value 30 mL/min/1.73m2 or less).3) A person with hypersensitivity to ivermectin.4) A person with a history of severe drug allergies such as Stevens-Johnson syndrome, toxic epidermal necrolysis.5) A person who has received the prohibited medication within the past month (within the past 6 months for biologics), or those who need to use the prohibited medication during the clinical trial period.6) Those who are scheduled to receive SARS-CoV-2 vaccination from the date of consent to the end of the follow-up period.7) A person who are currently participating in other clinical trials or who have participated in other clinical trials within 30 days before obtaining consent.8) In addition, a person who is determined to be unsuitable as a subject of this clinical trial by the principal investigator.

1) A woman who is in lactation period or who may be pregnant, or those who do not agree to prevent pregnancy by medically appropriate means for up to 7 days after study drug administration.Medically appropriate contraception means that using a combination of two or more of the following: not having sexual intercourse, taking surgical sterilization such as vasectomy or intrauterine device, taking oral contraceptive, using condom.2) A person who has severe liver damage (AST or ALT at the time of qualification test is more than 3 times the upper limit of institutional standard and total bilirubin is more than twice the upper limit of institutional standard value), renal disorder (eGFR of eligibility test value 30 mL/min/1.73m2 or less).3) A person with hypersensitivity to ivermectin.4) A person with a history of severe drug allergies such as Stevens-Johnson syndrome, toxic epidermal necrolysis.5) A person who has received the prohibited medication within the past month (within the past 6 months for biologics), or those who need to use the prohibited medication during the clinical trial period.6) A person who are currently participating in other clinical trials or who have participated in other clinical trials within 30 days before obtaining consent.7) In addition, a person who is determined to be unsuitable as a subject of this clinical trial by the principal investigator.

1) A woman who is in lactation period or who may be pregnant, or those who do not agree to prevent pregnancy by medically appropriate means for up to 7 days after study drug administration.Medically appropriate contraception means that using a combination of two or more of the following: not having sexual intercourse, taking surgical sterilization such as vasectomy or intrauterine device, taking oral contraceptive, using condom.2) A person who has severe liver damage (AST or ALT at the time of qualification test is more than 3 times the upper limit of institutional standard and total bilirubin is more than twice the upper limit of institutional standard value), renal disorder (eGFR of eligibility test value 30 mL/min/1.73m2 or less).3) A person with hypersensitivity to ivermectin.4) A person with a history of severe drug allergies such as Stevens-Johnson syndrome, toxic epidermal necrolysis.5) A person who has received the prohibited medication within the past month (within the past 6 months for biologics), or those who need to use the prohibited medication during the clinical trial period.6) A person who are currently participating in other clinical trials or who have participated in other clinical trials within 30 days before obtaining consent.7) In addition, a person who is determined to be unsuitable as a subject of this clinical trial by the principal investigator.